Business Segments · CapEx
Proprietary Products — CapEx
West Pharmaceutical Services Proprietary Products — CapEx decreased by 35.1% to $36.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 29.7%, from $51.90M to $36.50M. Over 4 years (FY 2021 to FY 2025), Proprietary Products — CapEx shows relatively stable performance with a -1.6% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ1 2026
How to read this metric
Higher spending indicates aggressive growth strategies or capacity upgrades, while lower spending may signal a focus on cash flow preservation.
Detailed definition
This represents the cash outflows used to acquire, upgrade, or maintain physical assets such as property, plants, and eq...
Peer comparison
Commonly reported as CapEx in segment disclosures for capital-intensive manufacturing companies.
Metric ID:
wst_segment_proprietary_products_capital_expendituresHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $54.50M | $54.50M | $54.50M | $59.33M | $59.33M | $59.33M | $59.33M | $64.78M | $64.78M | $64.78M | $64.78M | $61.10M | $58.50M | $47.80M | $79.10M | $51.90M | $48.50M | $47.70M | $56.20M | $36.50M |
| QoQ Change | — | +0.0% | +0.0% | +8.9% | +0.0% | +0.0% | +0.0% | +9.2% | +0.0% | +0.0% | +0.0% | -5.7% | -4.3% | -18.3% | +65.5% | -34.4% | -6.6% | -1.6% | +17.8% | -35.1% |
| YoY Change | — | — | — | — | +8.9% | +8.9% | +8.9% | +9.2% | +9.2% | +9.2% | +9.2% | -5.7% | -9.7% | -26.2% | +22.1% | -15.1% | -17.1% | -0.2% | -29.0% | -29.7% |
Range$36.50M – $79.10M
CAGR-8.1%
Avg YoY Growth-2.9%
Median YoY Growth+4.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's proprietary products — capex?
- West Pharmaceutical Services (WST) reported proprietary products — capex of $36.50M in Q1 2026.
- How has West Pharmaceutical Services's proprietary products — capex changed year-over-year?
- West Pharmaceutical Services's proprietary products — capex decreased by 29.7% year-over-year, from $51.90M to $36.50M.
- What is the long-term trend for West Pharmaceutical Services's proprietary products — capex?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's proprietary products — capex has grown at a -1.6% compound annual growth rate (CAGR), from $218.00M to $204.30M.
- What does proprietary products — capex mean?
- Cash spent on long-term investments like new factories or machinery for the proprietary segment.